Mediktor Acquires Sensely and Consolidates Its Position as a Leader in AI Healthcare Solutions

Mediktor, the leading digital healthcare company, has announced the acquisition of Sensely, a San Francisco-based, digital healthcare provider that pioneered an empathy-driven conversation platform to support hospital systems and insurance services with world-class member engagement. This consolidation of two world-leading artificial intelligence-driven solutions providers marks a major medical technology milestone, extending Mediktor’s global presence to […]

HUAV Partners with Mediktor for Improved Urgent Care Management

Hospital Universitario Arnau de Vilanova (HUAV) is a healthcare provider in Lleida, Alto Pirineo y Arán, and parts of La Franja in Aragón, Spain. Healthcare professionals were struggling with overcrowded waiting rooms, and the HUAV was looking for a digital solution to help manage urgent care effectively.    Read more

deepull appoints Didier Deltort to its Board of Directors

Didier Deltort is a Senior Advisor at Mérieux Equity Partners. Didier has spent over 30 years leading healthcare technology innovation and businesses around the world. His previous experience includes senior leadership positions at GE Healthcare, Boston Scientific, Zimmer Biomet and HP Inc. He will be the representative of the Pertinence Invest 2 Fund managed by UI Investissement […]

Peptomyc Appoints Selwyn Ho to its Board of Directors

Peptomyc S.L., a clinical stage company specialized in the development of protein therapeutics targeting the MYC oncoprotein for cancer treatment, today announced the appointment of Dr. Selwyn Ho, MB, BS, to its Board of Directors.   Read more

MYC targeting by OMO-103 in solid tumors: a phase 1 trial

Peptomyc presents results of their Ph1 study of OMO-103 in advanced solid tumours. OMO-103 is an inhibitor for MYC, one of the most wanted, long-considered, undruggable oncogenes. The trial has established the safety, tolerability and pharmacokinetic profile of OMO-103, advising on Ph2 design and identifying soluble factors with the potential as pharmacodynamic and predictive response […]

Peptomyc’s first MYC inhibitor, OMO-103, demonstrates safety and anti-tumor activity in a phase I clinical trial

Peptomyc is proud to announce that the results of the MYCure clinical trial have just been published in Nature Medicine (, demonstrating the unique potential of our lead first-in-class MYC inhibitor, OMO-103, to treat multiple oncological indications. Peptomyc takes pride in pioneering the blockade of a most-wanted target in cancer, and we believe this encouraging […]